Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Health benefits of TAVR over SAVR sustained at 1 year

Key clinical point: The late health status benefits seen with transcatheter aortic valve replacement (TAVR) were driven by a difference in the proportion of patients who experienced a large (20-point or greater) improvement in the Kansas City Cardiomyopathy Questionnaire–Overall Summary score.

Major finding: The researchers observed a persistent, although attenuated, benefit of TAVR over surgical aortic valve replacement in disease-specific health status at 6 and 12 months (mean difference in Kansas City Cardiomyopathy Questionnaire–Overall Summary of 2.6 and 1.8 points respectively; P less than .04 for both).

Study details: An analysis of 449 low-risk patients with severe aortic stenosis who were assigned to transfemoral TAVR using a balloon-expandable valve, and 449 who were assigned to surgery in the PARTNER 3 trial.

Disclosures: The PARTNER 3 quality of life substudy was funded by Edwards Lifesciences. Dr. Baron disclosed research funding and advisory board compensation from Boston Scientific and consulting fees from Edwards Lifesciences.

Citation:

Baron SJ. TCT 2019, Late-breaking Trials Session.